<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Emens, Leisha A.</style></author><author><style face="normal" font="default" size="100%">Butterfield, Lisa H.</style></author><author><style face="normal" font="default" size="100%">Hodi, F. Stephen</style></author><author><style face="normal" font="default" size="100%">Marincola, Francesco M.</style></author><author><style face="normal" font="default" size="100%">Kaufman, Howard L.</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Cancer immunotherapy trials: leading a paradigm shift in drug development</style></title><secondary-title><style face="normal" font="default" size="100%">Journal for ImmunoTherapy of Cancer</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016-12-01 00:00:00</style></date></pub-dates></dates><elocation-id><style  face="normal" font="default" size="100%">42</style></elocation-id><doi><style  face="normal" font="default" size="100%">10.1186/s40425-016-0146-9</style></doi><volume><style face="normal" font="default" size="100%">4</style></volume><issue><style face="normal" font="default" size="100%">1</style></issue><abstract><style  face="normal" font="default" size="100%">You do not have access to the full text of this article, the first page of the PDF of this article appears above.</style></abstract></record></records></xml>